Faicar

Faicar

SCHEMBL851406

NC(=O)c1ncn(C2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c1NC=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATIC P31939 3/20 1.00
FBP1 P09467 2/20 0.71
TAS1R3 Q7RTX0 5/20 0.53
TAS1R1 Q7RTX1 5/20 0.53
DNPH1 O43598 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PRKAB2 O43741 1/20 0.53
TRPM2 O94759 1/20 0.53
LDHA P00338 1/20 0.53
ADRB2 P07550 1/20 0.53
SRC P12931 1/20 0.53
ADORA1 P30542 1/20 0.53
P2RY2 P41231 1/20 0.53
P2RY1 P47900 1/20 0.53
PRKAG1 P54619 1/20 0.53
PRKAA2 P54646 1/20 0.53
PDE4D Q08499 1/20 0.53
KCNH2 Q12809 1/20 0.53
PRKAA1 Q13131 1/20 0.53
PDE3A Q14432 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Faicar SCHEMBL4360247 1.00 ATIC (1.00) ATICFBP1TAS1R3TAS1R1DNPH1
SCHEMBL30543778 0.87 ATIC (0.77) ATICFBP1TAS1R3TAS1R1DNPH1
SCHEMBL13153879 0.87 ATIC (0.77) ATICFBP1SMN1; SMN2KDM4ETDP1
SCHEMBL12918446 0.87 ATIC (0.77) ATICFBP1SMN1; SMN2KDM4ETDP1
SCHEMBL7139997 0.84 ATIC (0.73) ATICFBP1SMN1; SMN2ADORA1KDM4E
SCHEMBL7139991 0.84 ATIC (0.73) ATICFBP1SMN1; SMN2ADORA1KDM4E
SCHEMBL1230585 0.83 ATIC (1.00) ATICFBP1TAS1R3TAS1R1DNPH1
SCHEMBL20276955 0.83 ATIC (1.00) ATICFBP1TAS1R3TAS1R1DNPH1
Mizoribine Monophosphate SCHEMBL12727826 0.83 ATIC (0.80) ATICFBP1TAS1R3TAS1R1DNPH1
Mizoribine Monophosphate SCHEMBL16329889 0.83 ATIC (0.80) ATICFBP1TAS1R3TAS1R1DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8494779-B2 Method for screening essential metabolites in growth of microorganisms KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2013-07-23 US claimed
US-20100143911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 US claimed
US-20240018559-A1 GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS ACIES BIO D.O.O. (SI) 2024-01-18 US disclosed
EP-4251745-A1 GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS Acies Bio d.o.o. (SI) 2023-10-04 EP disclosed
CN-116745410-A Genetically engineered bacteria capable of producing cytokinins with isoprenoid side chains 阿西耶斯生物公司 2023-09-12 CN disclosed
EP-3532626-B1 METHOD FOR PRODUCING OBJECTIVE SUBSTANCE AJINOMOTO KK (JP) 2023-08-30 EP disclosed
US-11680279-B2 Method for producing objective substance AJINOMOTO CO., INC. (JP) 2023-06-20 US disclosed
WO-2022231037-A1 NOVEL VARIANT, AND METHOD FOR PRODUCING IMP USING SAME 씨제이제일제당 (주) 2022-11-03 WO disclosed
WO-2022231370-A1 NOVEL BIFUNCTIONAL PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE/IMP CYCLOHYDROLASE VARIANT AND METHOD FOR PRODUCING IMP USING SAME 씨제이제일제당 (주) 2022-11-03 WO disclosed
WO-2022112509-A1 GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS ACIES BIO D.O.O. (SI) 2022-06-02 WO disclosed
EP-4006139-A1 GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS Acies Bio d.o.o. (SI) 2022-06-01 EP disclosed
EP-2230312-A1 Probe compound for detecting and isolating enzymes and means and methods using the same Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-22 EP disclosed
US-20100143911-A1 METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 US disclosed
US-20090259451-A1 REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS UNIVERSITY OF DELAWARE (US) 2009-10-15 US disclosed
US-7585617-B2 For liberating and isolating component materials contained in a biological cell and for qualitative detection and quantitative determination of the liberated materials INSILICO BIOTECHNOLOGY GMBH (DE) 2009-09-08 US disclosed
US-20090186358-A1 Pathway Analysis of Cell Culture Phenotypes and Uses Thereof WYETH (US) 2009-07-23 US disclosed
WO-2009052186-A1 METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2009-04-23 WO disclosed
US-20070298484-A1 Method and Device for Thermal Conditioning of a Cell INSILICO BIOTECHNOLOGY GMBH (DE) 2007-12-27 US disclosed
EP-1720976-A1 METHOD AND DEVICE FOR THERMAL CONDITIONING OF A CELL Insilico Biotechnology Gmbh (DE) 2006-11-15 EP disclosed
WO-2005083054-A1 METHOD AND DEVICE FOR THERMAL CONDITIONING OF A CELL INSILICO BIOTECHNOLOGY GMBH (DE) 2005-09-09 WO disclosed